Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases

Bassam Abu-Wasel, Caolan Walsh, Valerie Keough, Michele Molinari

Abstract
Polycystic liver diseases (PLD) represent a group of genetic disorders in which cysts occur in the liver (autosomal dominant polycystic liver disease) or in combination with cysts in the kidneys (autosomal dominant polycystic kidney disease). Regardless of the genetic mutations, the natural history of these disorders is alike. The natural history of PLD is characterized by a continuous increase in the volume and the number of cysts. Both genders are affected; however, women have a higher prevalence. Most patients with PLD are asymptomatic and can be managed conservatively. Severe symptoms can affect 20% of patients who develop massive hepatomegaly with compression of the surrounding organs. Rarely, patients with PLD suffer from acute complications caused by the torsion of hepatic cysts, intraluminal cystic hemorrhage and infections. The most common methods for the diagnosis of PLD are cross sectional imaging studies. Abdominal ultrasound and computerized tomography are the two most frequently used investigations. Magnetic resonance imaging is more sensitive and specific, and it is a valuable test for patients with intravenous contrast allergies or renal dysfunction. Different treatment modalities are available to physicians caring for these patients. Medical treatment has been ineffective. Percutaneous sclerotherapy, transarterial embolization, cyst fenestration, hepatic resection and liver transplantation are indicated to specific groups of patients and have to be tailored according to the extent of disease. This review outlines the current knowledge of the pathophysiology, clinical course, diagnosis and treatment strategies of PLD.

© 2013 Baishideng. All rights reserved.

Key words: Polycystic liver disease; Hepatic; Epidemiology; Classification; Therapy; Genetic

Core tip: The management of patients with symptomatic polycystic liver disease is challenging. Among several treatments options, the most common interventions are: percutaneous cyst aspiration, fenestration, hepatic resection and liver transplantation. There is no consensus on the best treatment options and the optimal timing for interventions in symptomatic patients. In vision of these limitations, we reviewed the most recent literature and present a comprehensive article on this topic.

Abu-Wasel B, Walsh C, Keough V, Molinari M. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World J Gastroenterol 2013; 19(35): 5775-5786 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i35/5775.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i35.5775
INTRODUCTION

The association between polycystic liver disease (PLD) and autosomal dominant polycystic kidney disease (ADPKD) was described for the first time by Bristowe in 1856[1,2]. Initially, it was thought that PLD could develop only in the context of ADPKD[3]. The notion that isolated PLD might be a separate condition was proposed in the 1950s[4]. In 2003, a linkage analysis of eight Finnish families confirmed that PLD is genetically distinct from ADPKD[5]. Asymptomatic patients usually do not require any intervention[6]. In some patients, massive hepatomegaly can cause pain or compression of the adjacent gastrointestinal organs, vasculature, and diaphragm. This can have a significant effect on patients’ quality of life and performance status[8,9]. For these patients, the main aim is to reduce their symptoms by decreasing the liver volume[6-8]. Current surgical options include open or laparoscopic cyst fenestration with or without hepatic resection and orthotopic liver transplantation (OLT). Significant advances in surgical techniques have improved the outcomes of PLD patients. However, the selection of the appropriate approach remains a clinical challenge, and there is no consensus on the optimal timing and what represents the best therapeutic modality.

INCIDENCE AND GENETICS

ADPKD affects up to 0.2% of the general population[11]. On the other hand, isolated PLD has prevalence of less than 0.01%-0.13%. Both ADPKD and PLD are autosomal dominant and 75%-90% of patients with ADPKD have associated PLD[13]. In humans, PLD has been linked to mutations of four genes. Two genes (PKD1, locus 16p13.3, encoding polycystin-1 and PKD2, locus 4q21, and encoding polycystin-2) are predominantly associated with renal disease and less frequently with PLD. PKD1 mutations are more common and account for 85%-90% of the cases, whereas mutations in PKD2 affect approximately 10%-15% of patients[11]. The remaining two mutations (PRKCSH, locus 19p13.2, encoding the protein kinase C substrate 80K-H or hepatocystin; SEC63, locus 6q21, encoding the Sec63 protein) are linked only to the development of PLD[14]. However, these mutations explain just 25% to 40% of cases of PLD[11-13]. Comparative characteristics between ADPKD and PLD are summarized in Table 1.

PATHOPHYSIOLOGY

Malformation of the hepatic ductal plate and cilia of cholangiocytes is the main characteristic linked to the pathophysiology of PLD (Figure 1).

DUCTAL-PLATE MALFORMATION

The ductal plate is the anatomical template for the development of the intra-hepatic bile ducts[16]. Normal bile ducts arise from the ductal plate through a complex sequence of growth and apoptosis. Complexes of disconnected intralobular bile ductules (von Meyenburg complexes) are retained because they do not undergo apoptosis in PLD[16]. As a consequence, multiple cysts arise from progressive dilatation of these abnormal ductules[17-19] that display the same epithelium and structures of functioning cholangiocytes[20,21].

ABNORMAL PRIMARY CILIA

Cholangiocytes are the only ciliated cells in the liver. Cilia have mechanosensory capacity and modulate the intracellular levels of cAMP and Ca2+ when bent by the flow of bile. They also detect changes in osmolarity and composition of the bile[22-24]. Ciliary defects result in a decreased cytoplasmic level of Ca2+ and an increased cytoplasmic level of cAMP[25]. These changes are responsible for the hyperproliferation of cholangiocytes and for the cystogenesis that is a consequence of the altered balance between fluid secretion and absorption in the lumen of the biliary ducts[25].

NATURAL HISTORY AND RISK FACTORS FOR PLD

The natural history of PLD is characterized by a continuous increase in the volume and the number of cysts[13,26,27]. The annual growth of affected livers is in the range of 0.9%-3.2% of the initial hepatic volume[10,28-30]. Both genders are affected; however, women have a higher

---

**Table 1 Comparative epidemiological and genetic mutation characteristics of autosomal dominant polycystic kidney disease associated polycystic liver disease and isolated polycystic liver disease**

| Characteristics | ADPKD associated PLD | Isolated PLD |
|-----------------|----------------------|--------------|
| Prevalence      | 0.20%                | < 0.01%      |
| Type of inheritance | AD                   | AD           |
| Gene mutated    | PKD1; PKD2           | PRKCSH; SEC63|
| Encoded product | Polycystin-1;        | Hepatocystin; SEC63 |
| Chromosome locus | 16p13.3; 4q21        | 19p13.2; 6q21 |

AD: Autosomal dominant; ADPKD: Autosomal dominant polycystic kidney disease; PLD: Polycystic liver disease.
Intracranial arterial aneurysms can affect 6% of patients without a family history of ADPKD and up to 16% of patients with family history of ADPKD. Other common conditions are mitral-valve prolapse and colonic diverticulosis that can be detected in 25% of patients with PLD[11,45-48]. Screening for intracranial aneurysm by magnetic resonance angiography (MRA) is recommended only for patients with ADPKD, older than 30 years or for those patients with family history of hemorrhagic strokes or intracranial arterial aneurysms[46]. Screening for intracranial arterial aneurysms is also warranted in cases of a sudden severe headache, or for candidates to liver or kidney transplantation. Screening for mitral-valve prolapse is not recommended unless a cardiac murmur is ascertained during routine clinical examinations[47,48]. Finally, patients with ADPKD may have asymptomatic cysts within other organs, such as the pancreas, spleen, ovaries, and lungs[48]. Pancreatic cysts are the most common with a reported incidence of 9% among ADPKD patients older than 30 years[49-51].

DIAGNOSIS
The most common methods for the diagnosis of PLD are cross sectional imaging studies. Abdominal ultrasound (US) and computed tomography (CT) are the two most frequent investigations[52-54]. For hepatic cysts, MRI is more sensitive and specific, and it is a valuable test for patients with intravenous contrast allergies or renal dysfunction or when other studies are unable to satisfy the diagnostic needs[55]. Hepatic cysts have radiologic characteristics identical to benign developmental cysts. On US, they appear anechoic and well-circumscribed[53]. On CT and MRI, they have non-enhancing, well-circumscribed round walls with hypodense content[55]. On T2-weighted MRI and CT scans, they appear homogenously enhanced spherical lesions[55] (Figure 2B and C). The distinction between isolated PLD and ADPKD relies on the number of renal cysts, age at presentation and family history (Table 4). In adults, younger than 30 years with a positive family history, the diagnosis of ADPKD is established by radiologic evidence of at least two unilateral or bilateral cysts. At least two cysts in each kidney are necessary for the diagnosis of patients between the age of 30 to 59 years, and at least four cysts in each kidney for patients 60 years or older[48]. It is worth noting that at least one third of patients with isolated PLD may also have a few kidney cysts[56,57]. It has been proposed that

**ASSOCIATED EXTRA-HEPATIC DISEASES**

Intracranial arterial aneurysms can affect 6% of patients without a family history of ADPKD and up to 16% of patients with family history of ADPKD. Other common conditions are mitral-valve prolapse and colonic diverticulosis that can be detected in 25% of patients with PLD[11,45-48]. Screening for intracranial aneurysm by magnetic resonance angiography (MRA) is recommended only for patients with ADPKD, older than 30 years or for those patients with family history of hemorrhagic strokes or intracranial arterial aneurysms[46]. Screening for intracranial arterial aneurysms is also warranted in cases of a sudden severe headache, or for candidates to liver or kidney transplantation. Screening for mitral-valve prolapse is not recommended unless a cardiac murmur is ascertained during routine clinical examinations[47,48]. Finally, patients with ADPKD may have asymptomatic cysts within other organs, such as the pancreas, spleen, ovaries, and lungs[48]. Pancreatic cysts are the most common with a reported incidence of 9% among ADPKD patients older than 30 years[49-51].

**DIAGNOSIS**

The most common methods for the diagnosis of PLD are cross sectional imaging studies. Abdominal ultrasound (US) and computed tomography (CT) are the two most frequent investigations[52-54]. For hepatic cysts, MRI is more sensitive and specific, and it is a valuable test for patients with intravenous contrast allergies or renal dysfunction or when other studies are unable to satisfy the diagnostic needs[55]. Hepatic cysts have radiologic characteristics identical to benign developmental cysts. On US, they appear anechoic and well-circumscribed[53]. On CT and MRI, they have non-enhancing, well-circumscribed round walls with hypodense content[55]. On T2-weighted MRI and CT scans, they appear homogenously enhanced spherical lesions[55] (Figure 2B and C). The distinction between isolated PLD and ADPKD relies on the number of renal cysts, age at presentation and family history (Table 4). In adults, younger than 30 years with a positive family history, the diagnosis of ADPKD is established by radiologic evidence of at least two unilateral or bilateral cysts. At least two cysts in each kidney are necessary for the diagnosis of patients between the age of 30 to 59 years, and at least four cysts in each kidney for patients 60 years or older[48]. It is worth noting that at least one third of patients with isolated PLD may also have a few kidney cysts[56,57]. It has been proposed that
Involves direct handling of potentially infected blood products. Therefore, considerable effort has been devoted to search for alternatives to this procedure such as the use of 67Gallium scintigraphy and 18F-FDG-positron emission tomography (PET). In recent years, PET has become the most commonly used diagnostic test for the detection of infected renal and hepatic cysts[60,62,63]. However, the accuracy of this technique is still under investigation. The literature on the treatment of infected cysts in PLD patients is very scarce and based only on a few case reports. Most of patients will need parenteral broad spectrum antibiotic therapy with percutaneous drainage of the content of the cyst if their symptoms persists.

**CLASSIFICATION**

Several clinical classifications have been proposed to grade the severity of PLD.

**GIGOT’S CLASSIFICATION**

Gigot’s classification relies on imaging findings and was designed to identify the best candidates for fenestration of symptomatic cysts[38] (Figure 3): Type I: presence of less than 10 large hepatic cysts measuring more than 10 cm in maximum diameter. Type II: diffuse involvement of liver parenchyma by multiple cysts with remaining large areas of non-cystic liver parenchyma. Type III: presence of diffuse involvement of liver parenchyma by small and medium-sized liver cysts with only a few areas of

---

**INFECTED CYSTS**

Hepatic cysts may become infected, and cause life-threatening sepsis[58,59]. Often, infected hepatic cysts are responsible for recurrent episodes of fever without any other signs or symptoms. In these circumstances, the diagnosis can be quite difficult as the accuracy of imaging tests remain low due to the altered anatomy of the liver parenchyma[60]. A promising investigation technique for suspected infected hepatic cysts is In-111 WBC scan[61]. Several other tracers such as 99mTc-diphosphonates, 67Gacitrate, and 111In- or 99mTc-labeled leukocytes have also been used[62]. Although labeled leukocyte imaging is theoretically the test of choice for detecting most infections, it is labor intensive, not always available and involves direct handling of potentially infected blood products. Therefore, considerable effort has been devoted to search for alternatives to this procedure such as the use of 67Gallium scintigraphy and 18F-FDG-positron emission tomography (PET). In recent years, PET has become the most commonly used diagnostic test for the detection of infected renal and hepatic cysts[60,62,63]. However, the accuracy of this technique is still under investigation. The literature on the treatment of infected cysts in PLD patients is very scarce and based only on a few case reports. Most of patients will need parenteral broad spectrum antibiotic therapy with percutaneous drainage of the content of the cyst if their symptoms persists.

---

**Table 4 The ravine diagnostic criteria for autosomal dominant polycystic kidney disease**

| Patient’s age (yr) | Positive family history | Negative family history |
|-------------------|-------------------------|-------------------------|
| ≤ 30              | At least 2 cysts affecting 1 or both kidneys | At least 5 cysts |
| 31-59             | At least 2 cysts in each kidney | At least 5 cysts |
| ≥ 60              | At least 4 cysts in each kidney | At least 8 cysts |
normal liver parenchyma.

QUIAN’S CLASSIFICATION

Qian’s classification has been used in the context of familial screening and relies on the number of cysts and the presence of symptomatic hepatomegaly. (1) grade 0 - 0 cysts; (2) grade 1 - 1 to 10 cysts; (3) grade 2 - 11 to 20 cysts; (4) grade 3 - more than 20 cysts; and (5) grade 4 - more than 20 cysts and symptomatic hepatomegaly.

SCHNELLDORFER’S CLASSIFICATION

Schnelldorfer’s classification aims at differentiating patients who could benefit from resection or transplantation as summarized in Table 5.

TREATMENT

Most patients with PLD are asymptomatic and do not require any intervention. However, symptomatic PLD patients might require treatment when they experience severe dysfunction of organs around the liver due to the increased hepatic volume or when one or more cysts get tortured, infected or develop intra-cystic hemorrhages (Table 6).

AVOIDANCE OF EXPOSURE TO ESTROGENS

Observational and experimental studies have shown that PLD may worsen under the influence of estrogen during pregnancy or when patients are prescribed estrogen replacement therapy. Estrogen can increase both the number of liver cysts and their volume, therefore, hormonal therapy should be stopped in most symptomatic patients when appropriate.

NON-SURGICAL TREATMENTS

Medical management may be valuable in symptomatic patients with Gigot’s type II / III.

SOMATOSTATIN ANALOGUES

Somatostatin analogues are inhibitors of cAMP and they reduce the secretion of fluid and the proliferation of many cell types, including cholangiocytes. They also suppress the expression of insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), and other cytogenetic growth factors. In addition, somatostatin analogues inhibit the downstream signaling of these receptors. Two randomized controlled trials have recently demonstrated that after 6 to 12 mo, treatment with lanreotide, a long-acting somatostatin analogue, was associated with a significant reduction of liver volume in patients with PLD compared with placebo. However, the average hepatic volume reduction was only 3% to 5%. The severity of abdominal symptoms was also not significantly improved. Currently, somatostatin analogues are indicated only for a selected group of patients with symptomatic PLD in whom the risks for surgical intervention are not justified, or in whom the surgical intervention is technically challenging.

MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS

Mammalian target of rapamycin (m-TOR) inhibitors have immunosuppressive and antiproliferative effects. Sirolimus and Everolimus were studied in Phase-II prospective randomised control trials. None of the two drugs showed substantial therapeutic effects both in hu-
### INTERVENTIONAL RADIOLOGY: ARTERIAL EMBOLIZATION

Trans-catheter arterial embolization has been used since the early 2000s. Hepatic artery branches supplying the hepatic segments replaced by the cysts are targeted by using microcoils or polyvinyl alcohol particles measuring 150-250 μm in diameter. For patients with advanced PLD and multilobal disease, trans-catheter arterial embolization can be technically demanding. The largest series of patients treated with this modality included 30 patients who had a significant reduction of the volume of their cysts (6.667 ± 2.978 cm³ down to 4.625 ± 2.299 cm³), whereas the volume of the unaffected hepatic parenchyma increased. After several months, patients reported improvement of their symptoms and no major complications except for occasional post-embolization syndrome.

### PERCUTANEOUS SCLEROTHERAPY

This technique requires radiologically guided percutaneous aspiration of the content of the cysts followed by the injection of a sclerosing agent that inhibit the reaccumulation of fluid by damaging the epithelial lining the cysts. Symptomatic patients with one to five large dominant cysts (Gigot's type I) are suitable for percutaneous sclerotherapy. Most commonly, cysts with a diameter larger than 5 cm are candidates for this treatment. Puncturing of the cyst can be done with a 5 or 7 French catheter and sclerosing agents commonly used include ethanol, ethanolamine oleate, minocycline and tetracycline. Although a single session is often sufficient, some patients require more than one. Aspiration with sclerotherapy has an excellent safety profile, although severe abdominal pain can be caused by peritoneal irritation due to spillage of the sclerosing agent. The majority of patients who undergo percutaneous sclerotherapy has improved symptoms in the immediate period following the procedure, but only 20% will have partial, or full regression of their disease.

### SURGERY

Patient and treatment selection remain a clinical challenge. There is no consensus on selection criteria for surgery, the optimal timing, and technique. Current surgical options include fenestration, partial liver resection and OLT. Fenestration and partial liver resection are options for Gigot's type I and II patients. For Gigot's type III disease, fenestration and partial liver resection are often ineffective, and OLT should be considered as it is the only curative treatment. In general, several factors have to be considered before any surgical intervention is recommended: (1) The degree of cystic burden; (2) The distribution of the cysts; and (3) The proximity of the cysts to the main biliary ducts and portal and hepatic vein branches.

### SURGICAL PEARLS

In Gigot's type I or II, symptoms might not be related to the size of the entire liver but to the size of one or two large cysts. These patients can be treated similarly to those with simple cysts. Some hepatic segments such as V and VI are frequently spared and, therefore, surgical resection can be performed if the spared liver parenchyma is thought to be sufficient. Frequently, the right hepatic veins are compressed by cysts causing the formation of collateral circulation between the right and the middle hepatic veins that can be responsible for intraoperative bleeding during the parenchymal transaction.
FENESTRATION

Fenestration is a surgical technique that combines aspiration and surgical unroofing of the cyst. It has the advantage that multiple cysts can be treated in one session\(^\text{[48,82]}\). Fenestration is effective in symptomatic patients with Gigot's type I and II disease\(^\text{[48]}\). Patients with superficial and a limited number of large cysts are the best candidates for this procedure\(^\text{[48]}\). Fenestration may be achieved by laparotomy or laparoscopy\(^\text{[38]}\). Patients with the majority of their cysts located in the right posterior segments (VI, VII), or at the dome of the liver (segment VIII) may be better candidates for open fenestration because these cysts are difficult to be visualized and fenestrated by laparoscopic approach\(^\text{[38]}\). Published series describing open and laparoscopic fenestration are summarized in Table 7. Immediate symptom relief is achieved in 92% of the patients, whereas up to 25% experience recurrence of the cysts or symptoms\(^\text{[10]}\). Complication rate after fenestration is in the range of 23% while mortality is about 2%\(^\text{[10]}\). Complications include ascites, pleural effusion, hemorrhage and bile leakage\(^\text{[48]}\). Factors that predict failure of fenestration are previous abdominal procedures, deep-seated cysts, incomplete unroofing, cysts in segments VII-VIII, and the presence of diffuse PLD\(^\text{[38]}\).

| Ref. | No. of patients | Technique | Outcome | Complications | Follow-up (mo) |
|------|----------------|-----------|---------|---------------|---------------|
| van Erpucum et al\(^\text{[48]}\) | 15 | Open fenestration | 0% symptom recurrence | One mortality | Mean of 48 |
| Kabbej et al\(^\text{[48]}\) | 13 | Lap fenestration | 72% symptom recurrence | 54% morbidity | Mean follow-up 26 |
| Gigot et al\(^\text{[48]}\) | 10 | Open fenestration | 11% symptom recurrence | 60% morbidity | 73 mean follow-up |
| van Keimpema et al\(^\text{[48]}\) | 12 | Lap fenestration | Reduction in liver volume by 12.5% | Bile leak, vena cava occlusion | - |
| Pirenne et al\(^\text{[82]}\) | 4 | Lap fenestration | 100% symptom relief | 50% cyst recurrence | - |
| Liska et al\(^\text{[38]}\) | 7 | Lap fenestration plus open | Symptom and cyst recurrence in 20% | No mortality | Mean 41 |
| Bai et al\(^\text{[48]}\) | 10 | Lap fenestration | Symptom relief | 3 patients with minor complications. No mortality | Mean of 57 |
| Palanivelu et al\(^\text{[48]}\) | 4 | Lap fenestration | 100% cyst recurrence | - | - |
| Garea et al\(^\text{[48]}\) | 6 | Lap/Open fenestration | 16.7% symptom recurrence, 33.3% cyst recurrence | 50% morbidity | 5.36 |
| Neri et al\(^\text{[48]}\) | 3 | Lap fenestration | 100% symptom relief | 50% morbidity | - |
| Korompai et al\(^\text{[48]}\) | 8 | Lap fenestration | 0% symptom recurrence | - | - |
| Robinson et al\(^\text{[48]}\) | 11 | Lap fenestration | 54.5% symptom recurrence | - | - |
| Fiamingo et al\(^\text{[48]}\) | 6 | Lap fenestration | 30% symptom recurrence | 50% morbidity | 1.64 |
| Tocchi et al\(^\text{[48]}\) | 18 | Lap/open fenestration | - | - | - |
| Koperna et al\(^\text{[48]}\) | 39 | Open fenestration (n = 34); Lap (n = 5) | 21% symptom recurrence | - | 75 mean follow-up |
| Morino et al\(^\text{[48]}\) | 7 | Lap fenestration | 40% symptom recurrence | 44% morbidity rate | - |
| Farges et al\(^\text{[48]}\) | 13 | Open fenestration | 23% symptom recurrence | 69% morbidity | 84 follow-up |
| Ueno et al\(^\text{[48]}\) | 13 | Open fenestration (n = 6); Lap (n = 13) | 71% symptom recurrence | 30% morbidity | 37 mean follow-up |

LIVER TRANSPLANTATION

OLT is the only curative treatment for patients with severe PLD\(^\text{[87]}\). It is indicated in those patients with disabling symptoms that lead to decreased performance status and quality of life\(^\text{[10]}\). Patients with PLD usually have normal liver function and the current organ allocation system based on the Model for End-Stage Liver Disease (MELD) is often unable to assist this group of patients. For these patients, MELD exception criteria are needed\(^\text{[88,89]}\). Because of the shortness of available grafts, the need for life-long immunosuppression and the perioperative risks, OLT is indicated only for symptomatic patients.
Table 8  Summary of largest series published on the surgical techniques used for cystic fenestration and resection of symptomatic polycystic liver disease

| Ref.  | No. | Technique                        | Outcome                        | Complications                  | Follow-up (mo)       |
|-------|-----|----------------------------------|--------------------------------|--------------------------------|----------------------|
| Que et al[64] | 31  | Fenestration and resection       | 3% symptom recurrence          | 3% mortality, 58% morbidity    | Mean of 28           |
| Schnell Dorfer et al[64] | 124 | Fenestration and resection       | 93% symptom relief, 7.6% recurrent cyst formation | 72.6% morbidity, 3.2% mortality | Mean of 48           |
| Komprat et al[64] | 9   | Fenestration and resection       | 100% symptom relief, 11% recurrence | 33.35% morbidity              | 24-98                |
| Koperma et al[64] | 5   | Fenestration and resection       | 0% symptom recurrence          |                                |                      |
| Li et al[64] | 21  | Fenestration and resection       | 14.3% cyst recurrence          | 76.2% cyst morbidity, 0% mortality | 10-155               |
| Gamblin et al[64] | 51  | Fenestration and resection       | 3.9% symptom recurrence        | 17.6% morbidity, no mortality  | 1-49                 |
| Yang et al[64] | 7   | Fenestration and resection       | 100% symptom recurrence        | 100% morbidity, no mortality   | Mean of 20           |
| Vons et al[64] | 12  | Resection                       | 17% symptom recurrence         | 8% mortality, 83% morbidity    | Mean of 34           |
| Soravia et al[64] | 10  | Fenestration and resection       | 33% symptom recurrence         | 10% mortality, 20% morbidity   | Mean of 69           |
| Henne-Brums et al[64] | 8  | Fenestration and resection       | 50% symptom recurrence         | No mortality, 38% morbidity    | Mean of 15           |
| Vaufhey et al[64] | 5   | Fenestration and resection       | 0% symptom recurrence          | 0% mortality, 100% morbidity   | Mean of 14           |
| Sanchez et al[64] | 9   | Resection                       | 100% symptom relief, 100% recurrence | 0% mortality                  | Mean of 35           |
| Newman et al[64] | 9   | Fenestration and resection       | 88.9% symptom relief, 0% recurrence | 11.1% mortality, 55.6% morbidity | 2-44                |
| Iwatsuki et al[64] | 9   | Resection                       | 44.4% symptom relief, 44.4% recurrence | 0% mortality, 33.3% morbidity  | 12-180               |

Table 9  Summary of largest series published on the outcomes of patients undergoing liver transplantation for symptomatic polycystic liver disease

| Ref.  | No. of patients | Previous surgery | Combined liver and kidney transplantation | Morbidity | Mortality | Follow-up (mo) | Re-transplantation |
|-------|-----------------|------------------|---------------------------------------------|-----------|-----------|----------------|-------------------|
| Prenne et al[64] | 16  | 25%              | 6%                                          | 38%       | 13%       | Range 18-120   | 0%                |
| Taner et al[64] | 13  | -                | 54%                                         | 85%       | 31%       | -              | 0%                |
| Ueno et al[64] | 14  | -                | 36%                                         | 64%       | 21%       | -              | 0%                |
| Ueda et al[64] | 3   | -                | 0                                           | 33%       | 0%        | Mean of 32     | 0%                |
| Gustafsson et al[64] | 7  | 57%              | 43%                                         | 57%       | 43%       | Mean of 4      | 0%                |
| Swensson et al[64] | 9  | 44%              | 33%                                         | 44%       | 11%       | Mean of 26     | 11%               |
| Lang et al[64] | 17  | 35%              | 47%                                         | 47%       | 29%       | Mean of 12     | 12%               |
| Washburn et al[64] | 5  | 90%              | 20%                                         | 0%        | 20%       | Mean of 38     | 0%                |
| Starzl et al[64] | 4   | 0%               | 25%                                         | 0%        | 50%       | Mean of 38     | 0%                |

Table 10  Suggested management strategies based on Gigot’s classification

| Gigot’s I                  | Gigot’s II - III |
|----------------------------|------------------|
| Percutaneous sclerotherapy | Hepatic resection with fenestration if feasible |
| Fenestration              | Liver transplantation |

with Gigot’s type II and III disease.[12,48,90]. For patients undergoing OLT for PLD, perioperative morbidity is 40%-50%, whereas overall mortality is 10%-17%.[10]. In 3% of patients, retransplantation is required[11] and combined renal and liver transplantation are necessary in 42% of patients.[8,50]. Expected survival at 1- and 5-year are 93% and 92% for patients undergoing OLT alone while for patients who undergo combined liver and kidney transplant are 86% and 80% respectively.[10]. Published series reporting the outcomes of OLT for symptomatic PLD are summarized in Table 9.

HEPATIC RESECTION VS LIVER TRANSPLANTATION

The clinical decision between performing a hepatic resection with or without cyst fenestration[8] and referring the patient for OLT can be extremely difficult (Table 10). Hepatic resection with cyst fenestration implies leaving residual hepatic cysts that will eventually progress[10]. However, hepatic resection is associated with a lower risk of perioperative morbidity and mortality. OLT provides the only option for the cure of these patients but requires lifelong immunosuppression and has higher perioperative risks. Both resection and OLT are technically demanding, and peri-operative care can be complex. The risks and the benefits of each of the possible treatment options have to be carefully evaluated and put in the context of the clinical presentation and condition of each patient. Referral to a tertiary center with an experienced team of surgeons, hepatologists, and nephrologists is strongly recommended.

CONCLUSION

For patients with PLD, patients’ selection, timing and choice of treatments can be very challenging even for experienced physicians. For symptomatic patients, treatment strategies should be based on the degree and progression of their symptoms and the severity of other medical conditions. Symptomatic patients with large cysts or limited hepatic involvement might benefit from fenestration or sclerotherapy. Hepatic resection with or without fenestra-
tion should be favored in patients with diffuse involvement of the liver but with sufficient spared parenchyma. Finally, in the patient with diffuse disease, OLT is a valid option and should be pursued as primary therapy prior to the development of debilitating disease such as malnutrition and liver dysfunction that can significantly increase the risks of perioperative adverse events.

REFERENCES

1. Hoevenen IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JP, Everson GT. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int 2008; 28: 264-270 [PMID: 17927714 DOI: 10.1111/j.1445-2257.2007.01959.x]

2. Bristowe F. Cystic disease of the liver associated with similar disease of the kidneys. Trans Pathol Soc Lond 1856; 7: 229-234

3. Moschowitz E. Non-parasitic cysts (congenital) of the liver, with a study of aberrant bile ducts. Am J Med Sci 1906; 131: 674-699 [DOI: 10.1097/00000441-19060400-00011]

4. Feldman M. Polycystic disease of the liver. Am J Gastroenterol 1958; 38: 83-86 [PMID: 1349792]

5. Tahvanainen P, Tahvanainen E, Reijonen H, Halme L, Kääriäinen H, Höckerstedt K. Polycystic liver disease is genetically heterogeneous: clinical and linkage studies in eight Finnish families. J Hepatol 2003; 38: 39-43 [PMID: 12480558 DOI: 10.1016/S0168-8278(02)00348-3]

6. Torres VE. Treatment of polycystic liver disease: one size does not fit all. Am J Kidney Dis 2007; 49: 725-728 [PMID: 17533013 DOI: 10.1053/j.ajkd.2007.04.009]

7. Arnold HL, Harrison SA. New advances in evaluation and management of patients with polycystic liver disease. Am J Gastroenterol 2005; 100: 2569-2582 [PMID: 16279915 DOI: 10.1111/j.1572-0241.2005.00263.x]

8. Vauthy JN, Maddern GJ, Blumgart LH. Adult polycystic disease of the liver. Br J Surg 1991; 78: 524-527 [PMID: 2059797 DOI: 10.1002/bjs.1800780505]

9. Gründfeld JP, Albozue G, Jungers P, Landais P, Dana A, Droz D, Moyerot A, Laforgue B, Bouryztyn E, Franco D. Liver changes and complications in adult polycystic kidney disease. Adv Nephrol Necker Hosp 1985; 14: 1-20 [PMID: 2983516]

10. Drenth JP, Chrispijn M, Nagorency DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology 2010; 52: 2223-2230 [PMID: 21051111 DOI: 10.1002/hep.24036]

11. Temmerman F, Missiaen L, Bannens B, Laleman W, Cassim D, Verslype C, van Pelt J, Nevens F. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 2011; 34: 702-713 [PMID: 21790682 DOI: 10.1111/j.1365-2036.2011.04763.x]

12. Qian Q. Isolated polycystic liver disease. Adv Chronic Kidney Dis 2010; 17: 181-189 [PMID: 2019621 DOI: 10.1016/j.ackn.2009.12.005]

13. D’Agata ID, Jonas MM, Perez-Atayde AR, Guay-Woodford LM. Combined cystic disease of the liver and kidney. Semin Liver Dis 1994; 14: 215-228 [PMID: 7939783 DOI: 10.1055/s-2007-1007315]

14. Davila S, Guru L, Gharavi AG, Tian X, Onoe T, Qian Q, Li A, Cai Y, Kamath PS, King BF, Azumendini P, Tahvanainen P, Kääriäinen H, Höckerstedt K, Devuyst O, Pirson Y, Martin RS, Lifton RP, Tahvanainen E, Torres VE, Somlo S. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet 2004; 36: 575-577 [PMID: 15133510 DOI: 10.1038/ng1357]

15. Van Keimpema L, De Koning DB, Van Hoek B, Van Den Berg AP, Van Oijen MG, De Man RA, Nevens F, Drenth JP. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int 2011; 31: 92-98 [PMID: 20408955 DOI: 10.1111/j.1445-2257.2010.02247.x]

16. Desmet VJ. Ludwig symposium on biliary disorders—part I. Pathogenesis of ductal plate abnormalities. Mayo Clin Proc 1998; 73: 80-89 [PMID: 9443684 DOI: 10.1016/S0025-6196(11)63624-0]
Antonaci F, Capparelli E, Chicco A. Renal function in autosomal-dominant polycystic kidney disease. *Nat Rev Nephrol* 2009; 5: 221-228 [PMID: 19322187 DOI: 10.1038/nrneph.2009.13]

Russell RT, Pinson CW. Surgical management of polycystic kidney disease. *World J Gastroenterol* 2007; 13: 5052-5059 [PMID: 17876869]

Torra R, Nicolau C, Badenes C, Navarro S, Perez L, Estivill X, Darnell A. Ultrasonographic study of pancreatic cysts in autosomal dominant polycystic kidney disease. *Clin Nephrol* 1997; 47: 19-22 [PMID: 9021236]

Blyth H, Ockenden BG. Polycystic disease of kidney and liver presenting in childhood. *J Med Genet* 1971; 8: 257-284 [PMID: 5097134 DOI: 10.1136/jmg.8.3.257]

Milutinovic J, Schabel SI, Ainsworth SK. Autosomal dominant polycystic kidney disease with liver and pancreatic involvement in early childhood. *Am J Kidney Dis* 1989; 13: 340-344 [PMID: 2705452]

Levine E, Cook LT, Grantham J. Liver cysts in autosomal-dominant polycystic kidney disease: clinical and computed tomographic study. *AJR Am J Roentgenol* 1995; 164: 227-233 [PMID: 7531871 DOI: 10.2214/ajr.164.1.7531871]

Am J Kidney Dis 1994; 23: 824-827 [PMID: 7908078 DOI: 10.1016/S0140-6736(94)20205-5]

Carrim ZI, Murchison JT. The prevalence of simple renal cysts in black South African adults. *S Afr Med J* 1989; 71: 626-629 [PMID: 21288796 DOI: 10.1016/S0030-5898(97)90030-9]

Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thode Jr PA, Miller JP. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. *Clin J Am Soc Nephrol* 2006; 1: 64-69 [PMID: 17699192 DOI: 10.2215/CJN.00080605]

Vachha B, Sun MR, Siewert B, Eisenberg RL. Cystic lesions of the liver. *A JR Am J Roentgenol* 2011; 196: W355-W366 [PMID: 21427297 DOI: 10.2214/AJR.10.5292]

Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincad-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. *Lancet* 1994; 343: 824-827 [PMID: 7998078 DOI: 10.1016/S0140-6736(94)92026-5]

Carrim ZI. Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. *Clin Radiol* 2003; 58: 626-629 [PMID: 12887956 DOI: 10.1016/S0009-9260(03)00165-X]

Chauveau D, Fakhouri F, Grünfeld JP. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. *J Am Soc Nephrol* 2000; 11: 1767-1775 [PMID: 10966503]

Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. *Lancet* 2007; 369: 1287-1301 [PMID: 17434445 DOI: 10.1016/S0140-6736(07)60801-1]

Migali G, Annet L, Lonneux M, Devuyst O. Renal cyst infection in autosomal dominant polycystic kidney disease. *Nephrol Dial Transplant* 2008; 23: 404-405 [PMID: 17913735 DOI: 10.1093/ndt/gfm665]

Lahiri SA, Halfi GA, Speeg KV, Esterl RM. In-111 WBC scan localizes infected hepatic cysts and confirms their complete resection in adult polycystic kidney disease. *Clin Nucl Med* 1998; 23: 33-34 [PMID: 9442963 DOI: 10.1097/00003072-199801000-00001]

Soiusan M, Sberro R, Wartski M, Fakhouri F, Pecking AP, Alberini JL. Diagnosis and localization of renal cyst infection by 18F-fluorodeoxyglucose PET/CT in polycystic kidney disease. *Ann N Y Acad Sci* 2008; 1129: 529-531 [PMID: 18670861 DOI: 10.1111/j.1749-6632.2008.03609.x]
mography in autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 2003; 41: E18-E21 [PMID: 12776306 DOI: 10.1016/S0272-6386(03)00586-8]

64 **Schnell dorfer T**, Torres VE, Zakaria S, Rosen CB, Nagorney DM. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. *Am Surg* 2009; 250: 112-118 [PMID: 19561475 DOI: 10.1097/SLA.0b013e3181d83dc]

65 **Alvaro D**, Gigliozzi A, Attili AF. Regulation and deregulation of cholangiocyte proliferation. *J Hepatol* 2000; 33: 333-340 [PMID: 10952254 DOI: 10.1016/S0168-8272(00)00377-3]

66 **Mohler LN**, Stidsen CE, Hartmann B, Holst J. Somatostatin receptors. *Biochim Biophys Acta* 2003; 1616: 1-84 [PMID: 14507041 DOI: 10.1016/S0005-2736(03)00235-9]

67 **Heisler S**, Srikant CB. Somatostatin-14 and somatostatin-28 pretreatment down-regulate somatostatin-14 receptors and have biphasic effects on forskolin-stimulated cyclic adenosine, 3',5'-monophosphate synthesis and adrenocorticotropic hormone release in mouse anterior pituitary tumor cells. *Endocrinology* 1985; 117: 217-225 [PMID: 2861077 DOI: 10.1210/endo-117-1-217]

68 **Jakobs KH**, Gehring U, Gaugler B, Pfeuffer T, Schultz G. Occurrence of an inhibitory guanine nucleotide-binding regulatory subunit of the adenylyl cyclase system in cyc- variants of S49 lymphoma cells. *Eur J Biochem* 1983; 130: 605-611 [PMID: 6297910 DOI: 10.1111/j.1432-1323.1983.tb07192.x]

69 **Tan CK**, Podila PV, Taylor JE, Nagorney DM, Wiseman GA, Gores GJ, LaRusso NF. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. *Gastroenterology* 1995; 108: 1908-1916 [PMID: 7768398 DOI: 10.1016/0016-5085(95)90157-4]

70 **Pyronnet S**, Bousquet C, Najib S, Azar R, Lakhlai H, Susini C. Antitumor effects of somatostatin. *Mol Cell Endocrinol* 2008; 286: 230-237 [PMID: 18359151 DOI: 10.1016/j.mce.2008.02.002]

71 **Walz G**. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? *Nephrol Dial Transplant* 2006; 21: 1752-1757 [PMID: 16705023 DOI: 10.1093/ndt/gfl246]

72 **Serra AI**, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Walz G. Inhibitors of S49 lymphoma cells. *Gut* 2004.046524 [PMID: 14509984 DOI: 10.1016/j.gut.2004.046524]

73 **Everson GT**, Taylor MR, Doctor RB. Polycystic disease of the liver. *Hepatology* 2004; 40: 774-782 [PMID: 15382167]

74 **Freeman RB**, Gish RG, Harper A, Davis GL, Vierling J, Lieb LeBron M, Klintmalm G, Blazek J, Hunter R, Punch J. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. *LIVER Transpl* 2006; 12: S128-S136 [PMID: 17123284 DOI: 10.1002/ilt.20979]

75 **Arrazola L**, Mook D, Gish RG, Everson GT. Model for end-stage liver disease (MELD) exception for polycystic liver disease. *Liver Transpl* 2006; 12; S110-S111 [PMID: 17123287 DOI: 10.1002/ilt.20974]

76 **Kirchner GI**, Riffat K, Cantz T, Nashan B, Terkamp C, Becker T, Strassburg C, Barg-Hock H, Wagner S, Lück R, Klemmnapfer J, Manos MP. Outcome and quality of life in patients with polycystic liver disease after live or combined liver-kidney transplantation. *LIVER Transpl* 2006; 12: 1268-1277 [PMID: 16741930 DOI: 10.1002/ilt.20780]

77 **Rasmussen A**, Davies HF, Jamieson NV, Evans DB, Calne RY. Combined transplantation of liver and kidney from the same donor protects the kidney from rejection and improves kidney graft survival. *Transplantation* 1995; 59: 919-921 [PMID: 7701955]

78 **Pirinen J**, Aerts R, Young K, Gunson B, Koshiba T, Fourreau I, Mayer D, Buckels J, Mirza D, Roskams T, Elias E, Nevens F, Ferrery J, McMaster P. Liver transplantation for polycystic liver disease. *LIVER Transpl* 2001; 7: 238-245 [PMID: 11244166 DOI: 10.1053/jtts.2001.22179]

79 **Szabó LS**, Takacs I, Arkosy P, Sápy P, Szentkereszty Z. Laparoscopic treatment of nonparasitic hepatic cysts. *Surg
Abu-Wasel B et al. Polycystic liver disease

Endosc 2006; 20: 595-597 [PMID: 16437277 DOI: 10.1007/s00464-005-0266-6]

94 Martin JF, McKinley AJ, Currie EJ, Holmes P, Garden OJ. Tailoring the management of nonparasitic liver cysts. Ann Surg 1998; 228: 167-172 [PMID: 9712560 DOI: 10.1097/000005 18-19980800-00004]

95 Liska V, Treska V, Mirka H, Skalicky T, Sutnar A, Ferda K. [Treatment strategy in non-parasitic benign cysts of the liver]. Rozhl Chir 2008; 87: 512-516 [PMID: 19110943]

96 Bai XL, Liang TB, Lu JH, Yang N, Zhang HB, Zhou XP. Combined hepatic resection with fenestration for highly symptomatic polycystic liver disease. A report on seven patients. World J Gastroenterol 2004; 10: 2598-2601 [PMID: 15309916]

97 Vons C, Chauveau D, Martinod E, Smaleda C, Capron F, Grunfeld JP, Franco D. [Liver resection in patients with polycystic liver disease]. Gastroenterol Clin Biol 1998; 22: 50-54 [PMID: 9762166]

98 Soravia C, Mentha G, Giostra E, Monelli P, Rohrer A. Surgery for adult polycystic liver disease. Surgery 1995; 117: 272-275 [PMID: 7878532 DOI: 10.1016/S0003-2660(95)80201-6]

99 Henne-Bruns D, Klomp H, Kremer B. Non-parasitic liver cysts and polycystic liver disease: results of surgical treatment. Hepatogastroenterology 1993; 40: 1-5 [PMID: 8462920]

100 Vauley JN, Maddern GJ, Kolbinger B, Baer HU, Blumgart LH. Clinical experience with adult polycystic liver disease. Br J Surg 1992; 79: 562-565 [PMID: 1611453 DOI: 10.1012/bjs.1800790629]

101 Sanchez H, Gagner M, Rossi RL, Jenkins RL, Lewis WD, Munson JL, Brach J. Surgical management of nonparasitic cystic liver disease. Am J Surg 1991; 161: 113-18; discussion 113-18 [PMID: 1987844 DOI: 10.1016/0002-9610(91)90570-S]

102 Newman KD, Torres VE, Rakela J, Nagorney DM. Treatment of highly symptomatic polycystic liver disease. Preliminary experience with a combined hepatic resection-fenestration procedure. Ann Surg 1990; 212: 30-37 [PMID: 2363601 DOI: 10.1097/00000658-199007000-00005]

103 Ivatsuki S, Starzl TE. Personal experience with 411 hepatic resections. Ann Surg 1988; 208: 421-434 [PMID: 3178330 DOI: 10.1097/00000658-198810000-00004]

104 Tamer B, Willingham DL, Hewitt WR, Grewal HP, Nguyen JH, Hughes CB. Polycystic liver disease and liver transplantation: single-institution experience. Transplant Proc 2009; 41: 3769-3771 [PMID: 19917384 DOI: 10.1016/j.transproceed.2009.05.043]

105 Ueno T, Barri YM, Netto CJ, Martin A, Onaca N, Sanchez EQ, Chinnakota S, Randall HB, Dawson S, Levy MG, Goldstein RM, Klintmalm GB. Liver and kidney transplantation for polycystic liver and kidney-renal function and outcome. Transplantation 2006; 82: 501-507 [PMID: 16926594 DOI: 10.1097/01.tp.0000231712.75645.7a]

106 Ueda M, Egawa H, Okie F, Taira K, Uryuhara K, Fujimoto Y, Kozaki K, Tanaka K. Living-donor liver transplantation for polycystic liver disease. Transplantation 2004; 78: 480-481 [PMID: 14966436 DOI: 10.1097/01.HT.0000110319.60723.31]

107 Gustafsson BI, Friman S, Mjornstedt L, Olausson M, Backman L. Liver transplantation for polycystic liver disease: indications and outcome. Transplant Proc 2003; 35: 813-814 [PMID: 12644149 DOI: 10.1016/s0041-1345(03)00881-2]

108 Swenson K, Seu P, Kinkhabwala M, Maggard M, Martin P, Goss J, Busuttil R. Liver transplantation for adult polycystic liver disease. Hepatology 1998; 28: 412-415 [PMID: 9966005 DOI: 10.1002/hep.510280218]

109 Lang H, von We浮lwarz J, Oldhafer KJ, Behrend M, Schlitt HJ, Nashab B, Pichlmayr R. Liver transplantation in patients with polycystic liver disease. Transplant Proc 1997; 29: 2832-2833 [PMID: 9365580 DOI: 10.1016/S0041-1345(97)00669-9]

110 Washburn WK, Johnson LB, Lewis WD, Jenkins RL. Liver transplantation for adult polycystic liver disease. Liver Transpl Surg 1996; 2: 17-22 [PMID: 9346624 DOI: 10.1002/lts.500020105]

111 Starzil TE, Reyes J, Tzakis A, Mieses L, Todo S, Gordon R. Liver transplantation for polycystic liver disease. Arch Surg 1990; 125: 575-577 [PMID: 2353122 DOI: 10.1001/archsurg.1990.01410170210103]

P- Reviewers Drenth JPH, Hori T, Llado L, Schemmer P S- Editor Wen LL L- Editor A E- Editor Zhang DN

P- Reviewers Drenth JPH, Hori T, Llado L, Schemmer P S- Editor Wen LL L- Editor A E- Editor Zhang DN

P- Reviewers Drenth JPH, Hori T, Llado L, Schemmer P S- Editor Wen LL L- Editor A E- Editor Zhang DN

P- Reviewers Drenth JPH, Hori T, Llado L, Schemmer P S- Editor Wen LL L- Editor A E- Editor Zhang DN
